At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,428 enrolled
Drug / intervention
Nivolumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen
In Brief
A Phase 3 clinical trial evaluating Nivolumab for Non Small Cell Lung Cancer (NSCLC). Completed, enrolled 1,428 participants across 134 sites in 2 countries.
Detailed Summary
The purpose of this study is to estimate the incidence and characterize the outcome of high grade, select adverse events in subjects with advanced or metastatic NSCLC treated with Nivolumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer (NSCLC)
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 2014
Enrollment StartApr 2014
Primary CompletionOct 2021
TodayJul 2026
First PostedFeb 19, 2014
Enrollment StartApr 9, 2014
Primary CompletionOct 6, 2021
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 12.4 years ago
Interventions
Nivolumabdrug